Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
ST. LOUIS, Jan. 27, 2017 -- GeneriCo, LLC (“GeneriCo”), a global generic specialty pharmaceutical company, is pleased to announce that George R. Stevenson has joined the Company’s Board of Directors as the new Chairman of the Board. Mr. Stevenson brings deep generic and brand pharmaceutical expertise to the GeneriCo Board and is a seasoned pharmaceutical executive with many years of leadership in this dynamic marketplace. Mr. Stevenson most recently served as the President and Chief Executive Officer of Kremers Urban Pharmaceuticals (Division of UCB, Inc.) which was acquired in 2015 by Lannett Company, Inc. for $1.23B.
At Kremers Urban, George Stevenson led the Company’s growth from minimal value in 2007 to $1.23 billion in 2015. As part of this growth, Mr. Stevenson oversaw the approval of 12 FDA approved products, with another 30 products added to the R&D portfolio. Prior to Kremers Urban, Mr. Stevenson was Vice President of Generic Business & Trade Affairs at Endo Pharmaceuticals, and prior to that was successful during his professional career at Sandoz Inc. (Division of Novartis AG), Apothecon (Division of BMS), United Research Laboratories and Sun Company.
Tom Brya, CEO GeneriCo, stated, “We are thrilled to add George Stevenson to our Board of Directors. He will bring a depth of generic pharmaceutical expertise and leadership to add to our Board. His guidance will be invaluable as our ANDA pipeline products progress to approval and launch.”
About GeneriCo
GeneriCo is a generic pharmaceutical company focused on developing and marketing niche, high barrier drugs in the U.S. utilizing its proprietary data-driven, algorithm-based product selection process. The Company employs a four-pillar collaboration business strategy capitalizing on management’s deep industry knowledge and experience to collaborate with partners on the discovery, formulation, development and manufacture of generic drugs. The Company expects its 1st internally-developed ANDA to be filed in 2017, with a total of 2 ANDAs filed by the end of 2017.
GeneriCo is led by a management team with 195 years of combined experience in formulation, manufacturing and commercial leadership. The team has successfully filed and launched over 200 generic drugs and created more than $30B of firm value.
For more information, please visit www.genericopharma.com
GeneriCo Investor Contact: Deborah Knobelman, PhD – Chief Financial Officer Phone Number: +1.646.221.5830 Email: [email protected]
